Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and DLI After Allo SCT in Very High Risk MDS or AML
NCT03454984Phase 2Unknown
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2018
- Primary completion
- Sep 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, single-arm trial of guadecitabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Drugs
guadecitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03454984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454984.